(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -14.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Novavax's revenue in 2025 is $682,162,000.On average, 5 Wall Street analysts forecast NVAX's revenue for 2025 to be $86,251,092,199, with the lowest NVAX revenue forecast at $56,568,904,085, and the highest NVAX revenue forecast at $177,041,207,638. On average, 4 Wall Street analysts forecast NVAX's revenue for 2026 to be $80,593,397,570, with the lowest NVAX revenue forecast at $53,850,637,156, and the highest NVAX revenue forecast at $142,926,153,454.
In 2027, NVAX is forecast to generate $66,053,082,161 in revenue, with the lowest revenue forecast at $60,930,998,708 and the highest revenue forecast at $73,923,992,941.